<DOC>
	<DOC>NCT01898624</DOC>
	<brief_summary>To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.</brief_summary>
	<brief_title>Specified Drug Use-results Survey of Betanis Tablets</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>diagnosed as OAB and treated with mirabegron diagnosed as glaucoma (including normal tension glaucoma) having intraocular pressure measurement conducted more than twice within six months before the start of the mirabegron treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mirabegron</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>BetanisÂ®</keyword>
	<keyword>glaucoma</keyword>
</DOC>